May 02, 2026. 4 items curated for clinical relevance.
Above Threshold
Alabama Medical Cannabis Sales Gear for Spring 2026 Launch
This article previews the anticipated launch of medical cannabis sales in Alabama during spring 2026, signifying an important expansion for healthcare professionals specializing in cannabis who can now serve more patients in that region.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
This article highlights a new study indicating that cannabinoids CBD and CBG from cannabis may potentially reverse fatty liver disease, which could be significant for cannabis clinicians as these compounds might offer potential therapeutic options for this prevalent condition.
From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …
This article discusses the evolution of the cannabis industry, focusing on the rise of billion-dollar hemp drinks and regulatory challenges, which is significant for cannabis clinicians as understanding industry trends and regulatory changes can inform evidence-based medical cannabis practices.
New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …
This article introduces a new cannabis group focused on basing policy decisions on scientific research and patient experiences, which is significant for cannabis clinicians as it emphasizes evidence-based practices, improving the quality of care provided to patients.
Digest-Level Clinical Commentary
Have thoughts on this? Share it: